Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of High Dose Lenalidomide in Patients With Myelodysplastic Syndrome Refractory to Hypomethylating Agents

NCT01246076 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT01246076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01246076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of High Dose Lenalidomide in Patients With Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
August 31, 2015
Enrollment
24 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes